Francois Brisebois
Stock Analyst at Oppenheimer
(1.09)
# 3,685
Out of 4,944 analysts
88
Total ratings
29.07%
Success rate
-13.23%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $7.56 | +958.54% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $6.38 | +150.78% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $0.55 | +631.26% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $51.36 | +40.19% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $35.47 | +71.98% | 6 | Jan 13, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $10.15 | +97.04% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $5.16 | +442.64% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $13.40 | +123.88% | 8 | Oct 31, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $48.46 | +236.36% | 4 | Oct 31, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $11.64 | +372.71% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $7.44 | +101.61% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $5.22 | +14.94% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.44 | +350.82% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $17.15 | -18.37% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $15 | $3.78 | +296.83% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $15 | $2.58 | +481.40% | 4 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.47 | +912.15% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $14.18 | +358.39% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $5.36 | +86.57% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $1.91 | +161.78% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $7.63 | +1,892.14% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $18.82 | +91.29% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.22 | +27,086.23% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $3.08 | +175,224.68% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $2.23 | +393.27% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $2.87 | +527.18% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $4.22 | +1,084.83% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $1.42 | +228,069.01% | 1 | Feb 4, 2020 |
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $7.56
Upside: +958.54%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $6.38
Upside: +150.78%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $0.55
Upside: +631.26%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $51.36
Upside: +40.19%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $35.47
Upside: +71.98%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $10.15
Upside: +97.04%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $5.16
Upside: +442.64%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $13.40
Upside: +123.88%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $48.46
Upside: +236.36%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $11.64
Upside: +372.71%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $7.44
Upside: +101.61%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $5.22
Upside: +14.94%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $2.44
Upside: +350.82%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $17.15
Upside: -18.37%
Aug 9, 2024
Maintains: Outperform
Price Target: $13 → $15
Current: $3.78
Upside: +296.83%
Jun 26, 2024
Maintains: Outperform
Price Target: $11 → $15
Current: $2.58
Upside: +481.40%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $2.47
Upside: +912.15%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $14.18
Upside: +358.39%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.36
Upside: +86.57%
Apr 1, 2024
Reiterates: Outperform
Price Target: $5
Current: $1.91
Upside: +161.78%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $7.63
Upside: +1,892.14%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $18.82
Upside: +91.29%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.22
Upside: +27,086.23%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $3.08
Upside: +175,224.68%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $2.23
Upside: +393.27%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $2.87
Upside: +527.18%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $4.22
Upside: +1,084.83%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $1.42
Upside: +228,069.01%